Our founder Justin Allan says, “Good news guys! Looks like many peptides we used to use are going to come off the FDA banned list soon! So lets keep our fingers crossed that compounding pharmacies begin producing many of these again because I personally really miss providing BPC-157 to my patients. This article breaks down what you need to know and the best ways to maintain revenue streams in the midst of policy changes.”
As regulatory discussions around peptide compounding intensify in 2026, many clinicians, med spas, and patients are asking the same question: Are peptides legal again? Recent public comments from HHS Secretary Robert F. Kennedy Jr. have sparked renewed attention on the FDA’s Category 2 peptide list, which includes 19 compounds currently restricted from routine compounding under Section 503A.
During a recent appearance on The Joe Rogan Experience, RFK Jr. stated: “the fda is in the middle of, I think, within a couple of weeks we will have announced some kind of new action…and my hope is they are going to move to a place where people have access from ethical suppliers”
The statement was made during a recent episode of The Joe Rogan Experience podcast
While this statement has generated optimism, it is important to clarify what this does — and does not — mean under current FDA regulatory frameworks.
What Is the FDA 503A Bulk Drug Substances List?
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, traditional compounding pharmacies may prepare customized medications using certain bulk drug substances. The FDA maintains categories to determine eligibility for compounding.
- Category 1: Substances eligible for compounding.
- Category 2: Substances identified as presenting potential safety risks and not currently eligible for routine compounding.
- Category 3: Substances with insufficient information for full evaluation.
Category 2 designation does not equal FDA approval or formal prohibition. Instead, it reflects regulatory concern regarding safety data, immunogenicity, aggregation risk, sterility, and insufficient clinical evidence.
The 19 Peptides Currently Listed in Category 2
- BPC-157
- LL-37
- DSIP (Emideltide)
- Epitalon
- GHK-Cu (injectable)
- GHRP-2
- GHRP-6
- Ipamorelin acetate
- Kisspeptin-10
- KPV
- Melanotan II
- PEG-MGF
- MOTS-C
- Semax
- Thymosin beta-4 fragment
- AOD-9604
- CJC-1295
- Selank acetate
- Thymosin-alpha 1
What Reclassification Would Actually Mean
If certain peptides were moved from Category 2 to Category 1, licensed 503A pharmacies could compound them pursuant to a valid prescription. However, this would not mean the substances are FDA-approved drugs. They would still lack formal clinical indication approval, large-scale Phase III trials, and standardized dosing guidelines.
Compounding eligibility is not the same as FDA approval. This distinction is critical for both providers and patients.
Implications for Clinics and Med Spas
Providers must remain compliant with both federal and state regulations. Any regulatory change would still require: valid prescriptions, sourcing from licensed compounding pharmacies, proper documentation, and informed consent discussions with patients.
Clinics should avoid sourcing peptides from research chemical suppliers or gray-market distributors, as these carry significant quality and legal risks.
Peptide therapy is frequently implemented alongside hormone optimization protocols. As with all advanced therapies, providers should ensure appropriate training in endocrine physiology and regulatory compliance before integrating these services.
Related Course: Clinicians who want deeper education in this space may consider our advanced hormone replacement therapy training for providers, which focuses on evidence-based hormone management and patient safety.
Implications for Patients
Patients should understand that even if reclassification occurs, compounded peptides are not FDA-approved medications. Quality depends on the compounding pharmacy, and clinical oversight remains essential.
The Bigger Picture: Peptides in Anti-Aging & Regenerative Medicine
Peptide therapy does not exist in isolation. In many clinical settings, peptides are implemented alongside evidence-based metabolic and hormone therapies. For example, GLP-1 receptor agonists such as semaglutide and tirzepatide represent FDA-approved peptide therapies used in metabolic care, highlighting the important distinction between FDA-approved peptides and compounded peptides.
For clinicians seeking structured education in this area, our GLP-1 therapy training for nurse practitioners provides in-depth instruction on safety, prescribing considerations, and patient management.
Elite NP Perspective: Education Before Implementation
At Elite NP, our focus is education, compliance, and clinical excellence. Regulatory shifts can create confusion in the marketplace, but responsible practice requires a clear understanding of FDA frameworks, pharmacology, and ethical sourcing.
Related Course: For clinicians seeking structured, evidence-informed education on peptide therapy, pharmacodynamics, safety considerations, and regulatory context, our Anti-Aging and Peptide Therapy Course provides comprehensive training designed specifically for licensed providers.
Frequently Asked Questions
Are peptides legal again in the United States?
As of now, no formal FDA reclassification has been finalized. Public statements do not constitute regulatory action.
What is the FDA Category 2 peptide list?
It is a subset of bulk drug substances identified under 503A as presenting potential safety concerns and currently ineligible for routine compounding.
Can pharmacies compound BPC-157 again?
Only if it is formally reclassified to Category 1 and compounded pursuant to a valid prescription.
Is CJC-1295 FDA approved?
No. CJC-1295 is not FDA-approved.
Do patients need a prescription for peptides?
Yes. Compounded peptides require a valid prescription from a licensed provider.
